Relevant are drug classes and preparations that are mainly used in auto-inflammatory and autoimmune diseases: Tumour necrosis factor-α (TNF-α) inhibitors (adalimumab, infliximab, etanercept), CD20 antibodies (rituximab), CD52 antibodies (alemtuzumab), interleukin-6 (IL-6) antibodies (tocilizumab), IL-1 antagonists (anakinra, canakinumab) and B-cell activating factor inhibitors (belimumab) (Andrès et al., 2019). This evidence concerns the gene IL6 and autoimmune disease.